EMBRACE · Elucidating Mechanisms of Bladder Cancer Metastasis
Horizon 2020 — Marie Skłodowska-Curie Actions
- Duration
- 2018-09-01 → 2020-08-31
- EU contribution
- €177,599
- Participants
- 1
- Scheme
- MSCA-IF-EF-ST
Lines connect the coordinator with its partners.
Results in brief
Elucidating Mechanisms of Bladder Cancer Metastasis
Bladder cancer is one of the most prevalent cancers in the EU, frequently exhibiting invasion and metastasis and therefore associated with poor prognosis. Hepatocyte Growth Factor or HGF has been frequently associated with advanced stages of the disease, although targeting it or its receptors (c-Met) have failed in the clinic. This project aimed to delineate the precise downstream molecular mechanisms of HGF mediated metastasis in bladder cancer cells. Accordingly, this project had two major objectives. First to identify the downstream (targetable) intracellular signaling pathways that are responsible for HGF mediated bladder cancer metastasis. Thereafter, delineate the intra-cellular molecular mechanisms. The second objective was to develop biomarkers that can be potentially used to detect early invasive/metastatic behaviour of bladder cancer cells.
Data: CORDIS, © European Union
Project objective
Bladder cancer is the ninth most afflicted cancer in the world which affects people in both developing and developed countries; and European nations have some of the highest incidences. Poor prognosis and mortality rate is very often linked to formation of secondary tumour sites in these patients. In advanced stages of this cancer, cells strive to invade nearby tissues in a process called metastasis. More often than not, patients suffer more due to metastasis of cancer than through the original tumour. In this project, I will investigate the mechanisms which lead to bladder cancer metastasis; identify key components in the pathways and also test out specific inhibitors to mitigate the growth and/or metastasis. Having an acute knowledge of ‘how and which’ pathway(s) promote metastasis in bladder cancer should provide us with information so that specific components can be targeted. Moreover, the proposed study also focuses on developing state-of-the-art biomarker strategies to identify patient populations which will best benefit from our inhibitor therapies. This project will enable the translation of experimental results obtained from lab bench to understanding how some patients will best benefit from certain inhibitor therapies.
Original text from CORDIS.
Participants
- ACADEMISCH ZIEKENHUIS LEIDEN · LeidenCoordinatorNetherlands
Links
Data: CORDIS, © European Union